Lucinaktant
| Klinički podaci | |
|---|---|
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 825600-90-6 |
| ATC kod | R07AA30 |
| DrugBank | DB04897 |
| Hemijski podaci | |
| Formula | ? |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Respiratorno (inhalacija) |
Lucinaktant je sintetički peptidni surfaktant za intratrahealnu primenu. Ovaj tečni lek se koristi za tretiranje respiratornog distresnog sindroma novorođenčeti. FDA je odobrila ovaj lek u martu 2012.[1]
Lucinaktant se sastoji od sinapultida, hidrofobnog, 21 aminokiselinu dugog peptida (ponavljajuće jedinice leucina i lizina, KL4 peptid), koji je dizajniran da oponaša ljudski surfaktantni protein-B (SB-P). Specifičnije, on oponaša C-terminal amfipatičnog heliksnog domena tog proteina. On takođe sadrži fosfolipide (dipalmitoilfosfatidilholin, DPPC i palmitoiloleoil fosfatidilglicerol, POPG) i masnu kiselinu (palmitinsku kiselinu).[2][3][4][5][6][7][8][9][10]
- ↑ „FDA approves Surfaxin to prevent breathing disorder in premature infants”. Fda.gov. 6. 3. 2012.. Pristupljeno 20. 10. 2012.
- ↑ Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R: A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005 Apr;115(4):1030-8. PMID 15805381
- ↑ Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C, Mazela J, Liu G: One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics. 2007 Jun;119(6):e1361-70. Epub 2007 May 28. PMID 17533176
- ↑ Halliday HL, Speer CP: Lucinactant versus poractant-alpha in premature lambs. Pediatrics. 2006 Jun;117(6):2324-5; author reply 2325. PMID 16740886
- ↑ Gastiasoro-Cuesta E, Alvarez-Diaz FJ, Rey-Santano C, Arnaiz-Renedo A, Loureiro-Gonzalez B, Valls-i-Soler A: Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome. Pediatrics. 2006 Feb;117(2):295-303. PMID 16452346
- ↑ Donn SM: Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome. Expert Opin Investig Drugs. 2005 Mar;14(3):329-34. PMID 15833063
- ↑ Moen MD, Perry CM, Wellington K: Lucinactant: in neonatal respiratory distress syndrome. Treat Respir Med. 2005;4(2):139-45; discussion 146-7. PMID 15813666
- ↑ Doyle I: Lucinactant (Discovery Laboratories). IDrugs. 2002 Jul;5(7):696-702. PMID 12802703
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
